Literature DB >> 16142329

The cachectic mediator proteolysis inducing factor activates NF-kappaB and STAT3 in human Kupffer cells and monocytes.

Tammy M Watchorn1, Nabil Dowidar, Cornelis H C Dejong, Ian D Waddell, O James Garden, James A Ross.   

Abstract

A novel proteoglycan, proteolysis inducing factor (PIF), is capable of inducing muscle proteolysis during the process of cancer cachexia, and of inducing an acute phase response in human hepatocytes. We investigated whether PIF is able to activate pro-inflammatory pathways in human Kupffer cells, the resident macrophages of the liver, and in monocytes, resulting in the production of pro-inflammatory cytokines. Normal liver tissue was obtained from patients undergoing partial hepatectomy and Kupffer cells were isolated. Monocytes were isolated from peripheral blood. Following exposure to native PIF, pro-inflammatory cytokine production from Kupffer cells and monocytes was measured and the NF-kappaB and STAT3 transcriptional pathways were investigated using electrophoretic mobility shift assays. We demonstrate that PIF is able to activate the transcription factor NF-kappaB and NF-kappaB-inducible genes in human Kupffer cells, and in monocytes, resulting in the production of pro-inflammatory cytokines such as TNF-alpha, IL-8 and IL-6. PIF enhances the expression of the cell surface molecules LFA-1 and CD14 on macrophages. PIF also activates the transcription factor STAT3 in Kupffer cells. The pro-inflammatory effects of PIF, mediated via NF-kappaB and STAT3, are important in macrophage behaviour and may contribute to the inflammatory pro-cachectic process in the liver.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16142329

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  8 in total

Review 1.  Anorexia-Cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway.

Authors:  Carlos Camps; Vega Iranzo; Roy M Bremnes; Rafael Sirera
Journal:  Support Care Cancer       Date:  2006-07-04       Impact factor: 3.603

2.  Quercetin supplementation attenuates the progression of cancer cachexia in ApcMin/+ mice.

Authors:  Kandy T Velázquez; Reilly T Enos; Aditi A Narsale; Melissa J Puppa; J Mark Davis; E Angela Murphy; James A Carson
Journal:  J Nutr       Date:  2014-04-23       Impact factor: 4.798

3.  Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia.

Authors:  Kleiton Augusto Santos Silva; Jiangling Dong; Yanjun Dong; Yanlan Dong; Nestor Schor; David J Tweardy; Liping Zhang; William E Mitch
Journal:  J Biol Chem       Date:  2015-03-18       Impact factor: 5.157

4.  Pseudomonas DING proteins as human transcriptional regulators and HIV-1 antagonists.

Authors:  Andrew Suh; Valentin Le Douce; Olivier Rohr; Christian Schwartz; Ken Scott
Journal:  Virol J       Date:  2013-07-15       Impact factor: 4.099

Review 5.  Molecular Insights into Muscle Homeostasis, Atrophy and Wasting.

Authors:  Bianca Maria Scicchitano; Gabriella Dobrowolny; Gigliola Sica; Antonio Musarò
Journal:  Curr Genomics       Date:  2018-08       Impact factor: 2.236

6.  Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine.

Authors:  Michael H Gerber; Patrick W Underwood; Sarah M Judge; Daniel Delitto; Andrea E Delitto; Rachel L Nosacka; Bayli B DiVita; Ryan M Thomas; Jennifer B Permuth; Steven J Hughes; Shannon M Wallet; Andrew R Judge; Jose G Trevino
Journal:  Int J Mol Sci       Date:  2018-12-01       Impact factor: 5.923

Review 7.  The Metabolism Symbiosis Between Pancreatic Cancer and Tumor Microenvironment.

Authors:  Ying Li; Ju Zhang; Jie Xu; Shanglong Liu
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

Review 8.  Pancreatic cancer cachexia: a review of mechanisms and therapeutics.

Authors:  Carlyn R Tan; Patrick M Yaffee; Laith H Jamil; Simon K Lo; Nicholas Nissen; Stephen J Pandol; Richard Tuli; Andrew E Hendifar
Journal:  Front Physiol       Date:  2014-03-03       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.